❮ Back to Researchers

Anne Stephenson

MD, PhD

Scientist, Li Ka Shing Knowledge Institute

Email: anne.stephenson@unityhealth.to
Tel: 416-864-5406

Biography

Dr. Stephenson attended medical school and received her internal medicine training at the University of Toronto. She completed her training in Respiratory Medicine at the University of British Columbia in Vancouver in 2000 and has been working at St. Michael’s Hospital in the Adult CF Program since 2001. In 2010 she successfully completed her PhD in Clinical Epidemiology at the University of Toronto followed by a Post-Doctoral Fellowship in health services research. In addition to her clinical work, she oversees the Canadian CF Patient Registry (CCFR) and has utilized this resource for her own research in order to examine predictors of morbidity in CF. Most recently, she has linked the CCFR to the health administrative databases at IC/ES to examine emerging complications of CF in the ageing CF population. In addition, she collaborates with CF researchers internationally using national CF Registry data to conduct population-based epidemiologic research in CF.

Recent Publications

  1. Cheng, SY, Sahin, B, Abdulrahem, N, Eckford, PDW, Zysman-Colman, Z, Chilvers, M et al.. A Review of Newborn Screening Programs for Cystic Fibrosis: Are Current Protocols Appropriate for Canada's Diverse Population?. Pediatr Pulmonol. 2025;60 (11):e71386. doi: 10.1002/ppul.71386. PubMed PMID:41254982 PubMed Central PMC12641208.
  2. McMurray, J, Widger, K, Stephenson, AL, Stremler, R. Associations between actigraphic and self-reported sleep and mental health in adolescents and young adults with cystic fibrosis. J Pediatr Psychol. 2025; :. doi: 10.1093/jpepsy/jsaf103. PubMed PMID:41240392 .
  3. Stephenson, AL, Sykes, J, Stanojevic, S, Ma, X, Ostrenga, J, Todd, J et al.. Exploring reduced pulmonary exacerbation rates in cystic fibrosis: a pandemic or modulator effect?. ERJ Open Res. 2025;11 (5):. doi: 10.1183/23120541.00111-2025. PubMed PMID:41158496 PubMed Central PMC12557442.
  4. Burgel, PR, Orenti, A, Cromwell, E, Macek, M, Gutierrez, HH, Karadag, B et al.. Global prevalence of CFTR variants with respect to their responsiveness to elexacaftor-tezacaftor-ivacaftor. J Cyst Fibros. 2025;24 (6):1017-1026. doi: 10.1016/j.jcf.2025.10.007. PubMed PMID:41109837 .
  5. Semenchuk, J, Tuff-Gordon, E, Ma, X, Sykes, J, Cheng, SY, Aversa, M et al.. The Changing Transplant Landscape in the Era of Elexacaftor/Tezacaftor/Ivacaftor: A Word of Caution. Clin Transplant. 2025;39 (10):e70317. doi: 10.1111/ctr.70317. PubMed PMID:41004135 PubMed Central PMC12467477.
  6. Arya, R, Sharpe, I, Cheng, SY, Sykes, J, Ma, X, Stanojevic, S et al.. Elevated Rates and Earlier Onset of Nonpulmonary Comorbidities in Adults with Cystic Fibrosis: A Population-based Study. Ann Am Thorac Soc. 2025;22 (12):1874-1880. doi: 10.1513/AnnalsATS.202502-170OC. PubMed PMID:40720184 .
  7. Somayaji, R, Cheng, SY, Abdulrahem, N, Stanojevic, S, Eckford, P, Quon, BS et al.. Validating the Data Completeness and Accuracy of the Canadian Cystic Fibrosis Registry. Can Respir J. 2025;2025 :8893074. doi: 10.1155/carj/8893074. PubMed PMID:40661671 PubMed Central PMC12259333.
  8. Stephenson, AL, Sharpe, I, Sykes, J, Ma, X, Li, P, Stanojevic, S et al.. Primary care physician involvement increases likelihood of cancer screening in people with cystic fibrosis: A population-based study from Ontario, Canada. J Cyst Fibros. 2025;24 (4):698-703. doi: 10.1016/j.jcf.2025.04.004. PubMed PMID:40287331 .
  9. Cheng, SY, Raymond, C, Lambert, L, Husein, F, McFee, A, Tullis, E et al.. Characteristics, Clinical Outcomes, and Health Care Utilization of Women with Cystic Fibrosis and Their Live Newborns Delivered in the Hospital Setting. J Obstet Gynaecol Can. 2025;47 (10):102809. doi: 10.1016/j.jogc.2025.102809. PubMed PMID:40058495 .
  10. Love, AJ, Desai, S, Cheng, SY, Stephenson, AL, Stanojevic, S, Franciosi, AN et al.. Reduction in 3-Year Risk of Death or Lung Transplant for Individuals with Advanced Cystic Fibrosis Lung Disease Treated with Elexacaftor/Tezacaftor/Ivacaftor. Ann Am Thorac Soc. 2025;22 (2):302-305. doi: 10.1513/AnnalsATS.202405-451RL. PubMed PMID:39480171 .
Search PubMed

Affiliations & Other Activities

  • Assistant Professor, School of Graduate Studies, University of Toronto
  • Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto